BTIG Reiterates Rating on SNSE $SNSE
Key Points
- BTIG now rates Sensei Biotherapeutics, Inc. ($SNSE) "buy" with a $55.00 target.
- The Street's average $SNSE price target is $52.50 (Strong Buy).
- $SNSE last traded around $13.00.
BTIG reiterated its rating on Sensei Biotherapeutics, Inc. ($SNSE) to a "buy" rating, with a price target of $55.00 in a recent research note.
Sensei Biotherapeutics, Inc. ($SNSE) Stock
Sensei Biotherapeutics, Inc. Earnings
Analysts Set New Price Targets
About Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.